Investor Relations

Latest Financial Results

Q2 2019

Quarterly Results

Ended Jun 30, 2019

Stock Information

NYSE American





Market Cap

52 week Low/High

Day Low/High

Company Overview

Actinium Pharmaceuticals, Inc. ( is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate, Iomab-B, is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT). The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed acute myeloid leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Contact Information

Investor Relations
Actinium Pharmaceuticals, Inc.
275 Madison Avenue
Suite 702
New York, NY 10016

Transfer Agent
Action Stock Transfer
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: (801) 274-1088
F: (801) 274-1099